SGLT2 Inhibition in Combination With Diuretics in Heart Failure

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-11

Study Completion Date

2019-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The RECEDE-CHF trial is a single centre phase IV, randomised, double-blind, placebo-controlled, crossover trial conducted in NHS Tayside, Scotland comparing empagliflozin 25mg, to placebo in patients with Type 2 Diabetes and mild Chronic Heart Failure with left ventricular systolic dysfunction who are already on a loop diuretic. Renal physiological testing will be performed at two points on each arm to assess the effect of empagliflozin, on urinary volume, compared to placebo. The secondary outcomes are to assess the effect of empagliflozin in addition to loop diuretics on natriuresis, to assess the safety of add-on SGLT2 inhibitor therapy as measured by changes to serum creatinine and eGFR, to assess effects of empagliflozin on urinary protein/creatinine ratio, albumin/creatinine ratio and cystatin C when compared to placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

NCT06442280

Heart Failure Acute Diabetes Type 2 Heart Failure With Reduced Ejection Fraction +1 more

NOT_YET_RECRUITING PHASE4

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

NCT03027960

Heart Failure Type II; Diabetes

COMPLETED PHASE1

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

NCT05346653

Acute Decompensated Heart Failure

TERMINATED PHASE4

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

NCT05764057

AMI STEMI NSTEMI +1 more

RECRUITING PHASE3

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure

NCT05776043

Acute Decompensated Heart Failure

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 Diabetes (T2D) and Heart Failure (HF) are a frequent combination, where treatment options remain limited. There has been increasing interest around the sodium-glucose co-transporter 2 (SGLT2) inhibitors and their use in patients with HF. This is following publication of EMPA-REG OUTCOME trial that reported a 14% reduction in the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and \>30% reductions in cardiovascular mortality, overall mortality and HF hospitalisations in patients randomised to the SGLT2 inhibitor, empagliflozin, when compared to placebo. Data on the effect of SGLT2 inhibitor use with diuretics is limited. We hypothesize that, in the diabetic CHF population, SGLT2 inhibition may augment the effects of loop diuretics.

Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. The investigational medicinal product will be administered, followed by an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose.

This proof of concept trial will aim to shed light on the mechanism of the cardiovascular and renal outcomes demonstrated in the recent EMPA-REG study by documenting the influence of the SGLT2 inhibitors when used in combination with a loop diuretic on diuresis and natriuresis when compared to placebo.

The RECEDE-CHF trial is funded by the British Heart Foundation (BHF grant number: 807998). NAM is a BHF funded clinical research fellow.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

6 week period of Investigational Medicinal Product (Empagliflozin 25 mg od) or placebo. A 2 week washout period will then be observed, followed by the second arm with a further 6 week period of placebo or IMP. At week 1 and week 6 of each arm, detailed Renal Physiology Test days will be performed.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double-Blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Empagliflozin/Placebo

Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo

Group Type ACTIVE_COMPARATOR

Empagliflozin 25mg

Intervention Type DRUG

Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks

Placebo oral capsule

Intervention Type DRUG

Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks

Frusemide

Intervention Type DRUG

Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.

Placebo/Empagliflozin

Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks

Group Type ACTIVE_COMPARATOR

Empagliflozin 25mg

Intervention Type DRUG

Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks

Placebo oral capsule

Intervention Type DRUG

Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks

Frusemide

Intervention Type DRUG

Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Empagliflozin 25mg

Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks

Intervention Type DRUG

Placebo oral capsule

Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks

Intervention Type DRUG

Frusemide

Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jardiance Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of NYHA Functional class II-III HF with prior echocardiographic evidence of LVSD.
* On stable doses of furosemide, or alternative loop diuretic for at least one month.
* Stable Type 2 Diabetes (HbA1c, in the last 3 months, of 6.5% ≤ and ≤10.0%)
* eGFR ≥ 45 ml/min.
* Have stable HF symptoms for at least three months prior to consent
* On stable HF therapy for at least three months prior to consent
* Have not been hospitalised for HF for at least three months prior to consent.
* Women of childbearing potential must agree to take precautions to avoid pregnancy throughout the trial and for 4 weeks after intake of the last dose.

Exclusion Criteria

* A diagnosis of chronic liver disease and/or liver enzymes that are twice the upper limit of normal
* Systolic BP of \<95mmHg at screening visit.
* Participants on thiazide diuretics.
* Participants receiving renal dialysis
* Participants who have previously had an episode of diabetic ketoacidosis.
* Participants with type 1 diabetes mellitus
* Malignancy (receiving active treatment) or other life threatening disease.
* Pregnant or lactating women
* Participants with difficulty in micturition e.g. severe prostate enlargement
* Allergy to any SGLT2 inhibitor or lactose or galactose intolerance
* Past or current treatment with any SGLT2 inhibitor
* Participants who have participated in any other clinical interventional trial of an investigational medicinal product within 30 days.
* Participants who are unable to give informed consent
* Any other reason considered by the physician to be inappropriate for inclusion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No